2. Search Result
Search Result
Results for "

human nNOS

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12119
    GW274150
    2 Publications Verification

    		 NO Synthase Neurological Disease Inflammation/Immunology
    GW274150 is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC50=2.19 μM; Kd=40 nM) and rat iNOS (ED50=1.15 μM). GW274150 also displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 exerts a protective role in an acute model of lung injury inflammation .
    GW274150
  • HY-W003969
    Aminopicoline

    Ascensil; 2-Amino-4-methylpyridine

    		 NO Synthase Inflammation/Immunology
    Aminopicoline (Ascensil) is a potent and non-selective inhibitor of nitric oxide synthase (NOS) isoenzymes (iNOS, nNOS, eNOS). Aminopicoline competes with arginine at the substrate-binding site of nitric oxide synthase, reduces cellular nitric oxide production, inhibits the elevation of plasma nitrate, increases mean arterial pressure at high doses, and also serves as a basis for radiolabeled ligands to localize nitric oxide synthase binding sites. Aminopicoline can be used in the research of diseases associated with septic shock, joint inflammation, intestinal inflammation, and CNS inflammation .
    Aminopicoline
  • HY-108615
    CP-316819

    GPi 819

    		 Phosphorylase Cardiovascular Disease Neurological Disease Metabolic Disease
    CP-316819 (GPi 819) is a blood-brain barrier permeable glycogen phosphorylase inhibitor. CP-316819 inhibits hepatic glycogenolysis, safely reduces blood glucose in type 2 diabetes, and rarely induces hypoglycemia. CP-316819 increases brain glycogen reserves, protects neurons, alleviates hypoglycemic brain injury, and inhibits excessive platelet activation, exerting both neuroprotective and vasculoprotective effects. CP-316819 can be used in research related to hypoglycemia, thrombosis, autoimmune inflammatory diseases, and type 2 diabetes .
    CP-316819
  • HY-12119A
    GW274150 phosphate
    2 Publications Verification

    		 NO Synthase Neurological Disease Inflammation/Immunology
    GW274150 phosphate is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC50=2.19 μM; Kd=40 nM) and rat iNOS (ED50=1.15 μM). GW274150 phosphate displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 phosphate exerts a protective role in an acute model of lung injury inflammation .
    GW274150 phosphate
  • HY-W007524
    2-Aminoquinoline
    1 Publications Verification

    2-Quinolinamine

    		 NO Synthase Orthopoxvirus Infection Neurological Disease
    2-Aminoquinoline (2-Quinolinamine) is a promising compound as bioavailable nNOS inhibitor but suffers from low human nNOS inhibition, low selectivity versus human eNOS, and significant binding to other CNS targets. 2-Aminoquinoline exhibits antiviral activity against the vaccinia virus. 2-Aminoquinoline has the potential for the research of antineurodegenerative agents .
    2-Aminoquinoline
  • HY-W007524R
    2-Aminoquinoline (Standard)

    2-Quinolinamine (Standard)

    		 Reference Standards NO Synthase Orthopoxvirus Infection Neurological Disease
    2-Aminoquinoline (2-Quinolinamine) is a promising compound as bioavailable nNOS inhibitor but suffers from low human nNOS inhibition, low selectivity versus human eNOS, and significant binding to other CNS targets. 2-Aminoquinoline exhibits antiviral activity against the vaccinia virus. 2-Aminoquinoline has the potential for the research of antineurodegenerative agents .
    2-Aminoquinoline (Standard)
  • HY-170236
    nNOS-IN-5

    		NO Synthase Neurological Disease
    nNOS-IN-5 (Compound 9) is a potent human neuronal NOS (nNOS) inhibitor (Ki = 22 nM). nNOS-IN-5 exhibits excellent selectivity, with a 900-fold preference for human nNOS over human endothelial NOS (eNOS). nNOS-IN-5 can be used for neurodegenerative diseases study, such as Alzheimer's disease and Parkinson’s disease .
    nNOS-IN-5
  • HY-120865
    1,3-PBIT dihydrobromide

    		NO Synthase Inflammation/Immunology
    1,3-PBIT is a potent inhibitor of iNOS with a Ki of 47 nM compared to Ki values for eNOS and nNOS are 9 and 0.25 μM, respectively, for the purified human enzymes. Its inhibition in whole cells is greatly diminished, presumably to poor membrane permeability.
    1,3-PBIT dihydrobromide
  • HY-12119B
    GW274150 dihydrochloride

    		NO Synthase Neurological Disease Inflammation/Immunology
    GW274150 (dihydrochloride) is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC50=2.19 μM; Kd=40 nM) and rat iNOS (ED50=1.15 μM). GW274150 (dihydrochloride) displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 (dihydrochloride) exerts a protective role in an acute model of lung injury inflammation .
    GW274150 dihydrochloride
  • HY-181711
    nNOS-IN-6

    		NO Synthase Neurological Disease Cancer
    nNOS-IN-6 is a human neuronal nitric oxide synthase (hnNOS) inhibitor with a human hnNOS Ki of 16 nM, ~1800-fold selectivity over human eNOS, ~2900-fold selectivity over human iNOS, and a rat nNOS Ki of 34 nM.nNOS-IN-6 exhibits high effective permeability in PAMPA-BBB assays, crosses the blood-brain barrier, and shows sustained systemic exposure, low clearance, and robust brain penetration in mouse in vivo pharmacokinetic studies.nNOS-IN-6 can be used for the research of neurodegenerative diseases, melanoma .
    nNOS-IN-6
  • HY-181545A
    nNOS-IN-2 trihydrochloride

    		NO Synthase IFNAR Cancer
    nNOS-IN-2 trihydrochloride is a blood-brain barrier-permeable nitric oxide synthase (nNOS) inhibitor. nNOS-IN-2 trihydrochloride exhibits Ki values of 1.7 nM and 2.3 nM against human and rat nNOS, respectively, and shows high selectivity for human eNOS and iNOS. nNOS-IN-2 trihydrochloride also effectively reduces PD-L1 expression in human melanoma cells under both basal conditions and IFN-γ exposure. nNOS-IN-2 trihydrochloride can be used for the study of melanoma and related signaling pathways .
    nNOS-IN-2 trihydrochloride
  • HY-181642
    nNOS-IN-3

    		NO Synthase Neurological Disease Cancer
    nNOS-IN-3 (compound 4) is a selective neuronal nitric oxide synthase (nNOS) inhibitor with a human hnNOS Ki of 25 nM, rat rnNOS Ki of 18 nM, human heNOS Ki of 58140 nM, human hiNOS Ki of 6422 nM. nNOS-IN-3 binds to nNOS active sites via hydrogen bonds with Glu and chalcogen bonds with Met, fails to form chalcogen bonds with heNOS, and undergoes passive transcellular transport with minimal efflux liability. nNOS-IN-3 can be used for the research of neurodegenerative diseases and melanoma .
    nNOS-IN-3
  • HY-182519
    HMN-1180

    		NO Synthase Neurological Disease
    HMN-1180 is a selective, competitive neuronal nitric oxide synthase (nNOS) inhibitor with a Ki value of 5.4 μM against rat nNOS. HMN-1180 exerts no significant effect on endothelial nitric oxide synthase (eNOS) or inducible nitric oxide synthase (iNOS). HMN-1180 inhibits nitric oxide production. HMN-1180 can be used for the study of nNOS-related neuronal functional physiology .
    HMN-1180

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: